Silexion Sets 1-for-24 Reverse Stock Split to Address Nasdaq Bid Price Deficiency
Key Facts
Silexion Therapeutics announced on Nov. 9, 2026, a 1-for-24 reverse split of its common stock, saying the action aims to address a bid price deficiency and regain compliance with Nasdaq requirements. Adjusted trading begins at the market open on Nov. 11, after the split takes effect following the close of trading on Nov. 10. Under the plan, every 24 outstanding shares will be combined into one. Chief Executive Ilan Hadar said the move is intended to maintain the company's Nasdaq listing, support its capital structure and advance its clinical plan. The stock closed at $0.1452 on Nov. 6, the latest closing price available before adjusted trading begins.
The split will mathematically raise the stock's nominal price from $0.135 to $3.24, with the nominal value per share changing proportionately. The company will not issue fractional shares; participants in the DTC depository and settlement system entitled to fractional shares will receive a whole share, rounded up. The trading symbol SLXN will remain unchanged, while post-split shares will carry a new CUSIP number, G1281K163. The company said the new identifier applies to the adjusted shares that begin trading on Nov. 11. The consolidation changes the number of shares and the nominal value per share, but does not by itself establish that the market price will rise by the same amount.
Nasdaq Capital Market continued-listing rules set a minimum bid price of $1 per share. The company said in an earlier filing that it had closed below that level for 30 consecutive trading days and that Nasdaq notified it of the compliance deficiency on Sept. 25, 2026. According to its filing with the U.S. Securities and Exchange Commission, the company asked Nasdaq's hearing panel for an extension to comply through late November. It expected to receive a follow-up letter from Nasdaq at that time if it regained compliance. The split's effect therefore depends on whether the post-adjustment trading price meets the minimum within the extension period; the announcement does not mean the company has guaranteed that it will regain compliance or remain listed.
The company presented the split as part of efforts to support its capital structure and the financing flexibility needed to continue clinical execution. It said the expected higher nominal price could help address the bid price deficiency, broaden the investor base and improve its financing flexibility. However, company documents filed with the U.S. Securities and Exchange Commission warn there is no guarantee the market price will rise in proportion to the reduction in the number of shares. They also noted that liquidity could be adversely affected by a decline in the number of shares available for trading. The market response in price and liquidity after adjusted trading begins will therefore be among the factors to watch, while a change in nominal value alone does not establish a confirmed economic outcome for shareholders.
The move comes as Silexion said it is progressing through the active phase of its Phase 2/3 SIL204 trial for locally advanced pancreatic cancer. The company said it dosed its first patient in September 2026, and Hadar linked the split to supporting clinical execution as well as maintaining the listing. This follows a series of earlier reverse splits recorded in the company's filings: 1-for-9 on Nov. 27, 2024, then 1-for-15 on July 28, 2025, and 1-for-10 on May 28, 2026. Trading on the basis of the new split begins on Nov. 11, 2026, while the company expected a follow-up letter from Nasdaq in late November if it regained compliance. Meeting the $1 per-share threshold within the required period will be a key focus following the announcement.